Current trends in separation of plasmid DNA vaccines: A review

Ghanem, Ashraf; Healey, Robert D.; Adly, Frady G.

doi:10.1016/j.aca.2012.11.006

Cited by 77 publications

(35 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the increasing pharmaceutical potential of plasmid DNA (pDNA), which is typically purified using step gradient elution [16,17], only a single study applied DC/SDC approach to its purification [18]. The study demonstrated that conventional porous particle columns were not suited to the separation of any two substances varying considerably in molecular mass, whereas of separation of pDNA from host cell proteins (HCP) and endotoxin was achieved using a continuous bed column.…”

Section: Introductionmentioning

confidence: 99%

Sample displacement chromatography of plasmid DNA isoforms

Černigoj

Martinuč

Cardoso

et al. 2015

Journal of Chromatography A

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Sample displacement chromatography of plasmid DNA isoforms

Černigoj

Martinuč

Cardoso

et al. 2015

Journal of Chromatography A

View full text Add to dashboard Cite

“…The DNA vaccination process is performed as follows, the exogenous genes are cloned into a eukaryotic expression vector and the recombinant plasmid DNA is injected directly into the animal. These exogenous genes are subsequently expressed in vivo, and the generated antigens activate the immune system, triggering an immune reaction (19,20).…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Wei

Gan

Ren

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. In the present study a eukaryotic expression vector of varicella zoster virus (VZV) glycoprotein E (gE) was constructed and enabled to express in COS7 cells. Furthermore, a specific immune response against the VZV gE eukaryotic expression plasmid was induced in BALB/c mice. The VZV gE gene was amplified using polymerase chain reaction (PCR) and cloned into a eukaryotic expression vector, pcDNA3.1. The recombinant vector was subsequently transfected into COS7 cells using a liposome transfection reagent. The recombinant protein was instantaneously expressed by the transfected cells, as detected by immunohistochemistry, and the recombinant pcDNA-VZV gE plasmid was subsequently used to immunize mice. Tissue expression levels were analyzed by reverse transcription-PCR. In addition, the levels of serum antibodies and spleen lymphocyte proliferation activity were investigated. The amplified target gene included the full-length gE gene (~2.7 kb), and the recombinant expression vector induced gE expression in COS7 cells. In addition, the expression plasmid induced sustained expression in vivo following immunization of mice. Furthermore, the plasmid was capable of inducing specific antibody production and effectively stimulating T cell proliferation. Effective humoral and cellular immunity was triggered in the mice immunized with the VZV gE eukaryotic expression vector. The results of the present study laid the foundation for future research into a VZV DNA vaccine.

show abstract

“…Three principal mechanisms of antigen presentation are hypothesized: (1) somatic cell transfection (e.g. of keratinocytes or myocytes), (2) APC transfection, and (3) uptake of secreted antigen and presentation by professional Table 2 Advantages and disadvantages of pDNA vaccine [61].…”

Section: Detailed Mechanisms Of Dna Vaccinationmentioning

confidence: 99%

Applications of immunochemistry in human health: advances in vaccinology and antibody design (IUPAC Technical Report)

Klein

Templeton

Schwenk

2014

Pure and Applied Chemistry

View full text Add to dashboard Cite

This report discusses the history and mechanisms of vaccination of humans as well as the engineering of therapeutic antibodies. Deeper understanding of the molecular interactions involved in both acquired and innate immunity is allowing sophistication in design of modified and even synthetic vaccines. Recombinant DNA technologies are facilitating development of DNA-based vaccines, for example, with the recognition that unmethylated CpG sequences in plasmid DNA will target Toll-like receptors on antigen-presenting cells. Formulations of DNA vaccines with increased immunogenicity include engineering into plasmids with "genetic adjuvant" capability, incorporation into polymeric or magnetic nanoparticles, and formulation with cationic polymers and other polymeric and non-polymeric coatings. Newer methods of delivery, such as particle bombardment, DNA tattooing, electroporation, and magnetic delivery, are also improving the effectiveness of DNA vaccines. RNA-based vaccines and reverse vaccinology based on gene sequencing and bioinformatic approaches are also considered. Structural vaccinology is an approach in which the detailed molecular structure of viral epitopes is used to design synthetic antigenic peptides. Virus-like particles are being designed for vaccine deliveries that are based on structures of viral capsid proteins and other synthetic lipopeptide building blocks. A new generation of adjuvants is being developed to further enhance immunogenicity, based on squalene and other oil-water emulsions, saponins, muramyl dipeptide, immunostimulatory oligonucleotides, Toll-like receptor ligands, and lymphotoxins. Finally, current trends in engineering of therapeutic antibodies including improvements of antigen-binding properties, pharmacokinetic and pharmaceutical properties, and reduction of immunogenicity are discussed. Taken together, understanding the chemistry of vaccine design, delivery and immunostimulation, and knowledge of the techniques of antibody design are allowing targeted development for the treatment of chronic disorders characterized by continuing activation of the immune system, such as autoimmune disorders, cancer, or allergies that have long been refractory to conventional approaches.

show abstract

Current trends in separation of plasmid DNA vaccines: A review

Cited by 77 publications

References 76 publications

Sample displacement chromatography of plasmid DNA isoforms

Sample displacement chromatography of plasmid DNA isoforms

Immunogenicity of varicella zoster virus glycoprotein E DNA vaccine

Applications of immunochemistry in human health: advances in vaccinology and antibody design (IUPAC Technical Report)

Contact Info

Product

Resources

About